Bridgeway Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Bridgeway Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-128,000	Closed	-$1.82M	–	1316
2019 Q1	$1.82M	Buy	128,000 +65,000	+103%	+$604K	0.02%	563
2018 Q4	$178K	Sell	63,000 -25,000	-28%	-$82.3K	﹤0.01%	1235
2018 Q3	$304K	Hold	88,000	–	–	﹤0.01%	1252
2018 Q2	$282K	Hold	88,000	–	–	﹤0.01%	1262
2018 Q1	$216K	Buy	88,000 +38,000	+76%	+$114K	﹤0.01%	1263
2017 Q4	$280K	Hold	50,000	–	–	﹤0.01%	1228
2017 Q3	$278K	Buy	+50,000	New	+$268K	﹤0.01%	1220

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Bridgeway Capital Management's AXSM Position: Q2 2019 in Review

Bridgeway Capital Management sold out of Axsome Therapeutics (AXSM) in Q2 2019, closing a stake of 128,000 shares — an estimated $1.82M sold.

Bridgeway Capital Management first reported a position in AXSM in Q3 2017 and held it in 7 quarters. The position peaked at $1.82M in Q1 2019. 109 funds tracked by Wall St. Rank hold AXSM as of Q2 2019.

Bridgeway Capital Management reported no remaining Axsome Therapeutics position as of Q2 2019 after selling out during the quarter.
Bridgeway Capital Management sold 128,000 Axsome Therapeutics shares in Q2 2019, an estimated $1.82M.
Bridgeway Capital Management first reported a position in Axsome Therapeutics in Q3 2017 and held it in 7 quarters.
Bridgeway Capital Management's Axsome Therapeutics position peaked at $1.82M in Q1 2019.
109 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.